<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121913</url>
  </required_header>
  <id_info>
    <org_study_id>04ACL101</org_study_id>
    <nct_id>NCT01121913</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Four-way Crossover Pilot Study to Compare the Relative Bioavailability of Two Prototype Once-a-day Trazodone Hydrochloride Products and Two Marketed Reference Products Following an Equivalent Daily Dose Administration Under Fasting Conditions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <brief_summary>
    <textblock>
      The objectives of this study were:

        -  to compare the pharmacokinetic profiles of two prototype controlled-release (CR)
           trazodone hydrochloride (HCl) 300 mg tablets versus two reference products: Trittico® AC
           (2 x 150 mg CR tablets) and Desyrel® (3 x 100 mg IR (immediate-release) tablets) under
           fasting condition;

        -  to assess the controlled release properties of the two prototype formulations;

        -  to select a prototype formulation for further development;

        -  to validate the blood sampling schedule for future pivotal pharmacokinetic studies;

        -  to determine the appropriate sample size for pivotal studies based in the intra-subject
           variability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC(0-t)</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration.
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC(0-∞)</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on Cmax</measure>
    <time_frame>72 hours</time_frame>
    <description>Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t½.z)</measure>
    <time_frame>72 hours</time_frame>
    <description>Apparent terminal half-life (t½.z) of trazodone in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the Maximum Concentration (Tmax)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent First Order Terminal Rate Constant [λz]</measure>
    <time_frame>72 hours</time_frame>
    <description>Apparent First order terminal rate constant [λz] of trazodone in plasma expressed in 1/hours.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trazodone Contramid® OAD (test product 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone Contramid® OAD(test product 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triticco®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Desyrel®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.</description>
    <arm_group_label>Trazodone Contramid® OAD (test product 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.</description>
    <arm_group_label>Trazodone Contramid® OAD(test product 2)</arm_group_label>
    <other_name>Oleptro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.</description>
    <arm_group_label>Triticco®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.</description>
    <arm_group_label>Desyrel®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects 18 to 45 years of age (inclusive).

          -  Body mass within 10% of the ideal mass in relation to height and age, according to the
             BMI.

          -  Body mass not less than 70 kg. The normal total circulating blood volume in males and
             in females is about 71 mL/kg and 65 mL/kg of the body mass, respectively (Meyer,
             1988). No subject will have more than 13% of estimated blood volume taken during the
             study (Standards for the Practice of Blood Transfusion in South Africa, 1999).

          -  Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the &quot;normal ranges&quot; for the relevant
             laboratory tests (unless the clinical investigator considers the deviation to be
             irrelevant for the purpose of the study).

          -  Normal ECG and vital signs, or abnormalities which the clinical investigator does not
             consider a disqualification for participation in the study.

          -  Willingness to undergo pre- and post-study physical examinations, and pre- and post
             study laboratory investigations.

          -  Ability to comprehend and willingness to sign both statements of informed consent (for
             screening and phase-related procedures).

          -  Non-smoker or past smoker who stopped smoking at least 3 months before entering the
             study.

          -  For females, the following conditions are to be met:

               1. has been surgically sterilized, or

               2. is of childbearing potential, and all of the following conditions are met:

                    1. had a normal menstrual flow within 1 month before study entry, and

                    2. has a negative urine pregnancy test at screening. If this test is positive,
                       the subject will be excluded from the study before receiving study
                       medication. In the rare circumstance that a pregnancy is discovered after
                       the subjects received the study drug, every attempt must be made to follow
                       such subjects to term, and

                    3. must agree to use an accepted method of contraception (i.e., spermicide and
                       barrier methods or spermicide and intrauterine contraceptive device). The
                       subject must agree to continue with the same method throughout the study.
                       Hormonal contraceptives will be allowed, with a stable dose for at least one
                       month prior to the first intake of study medication.

        Exclusion Criteria:

          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional
             or intellectual problems likely to limit the validity of consent to participate in the
             study or limit the ability to comply with protocol requirements.

          -  History of, or current compulsive alcohol abuse (&gt; 10 drinks weekly), or regular
             exposure to other substances of abuse.

          -  Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the
             first administration of study medication except if this will not affect the outcome of
             the study in the opinion of the clinical investigator. Use of hormonal contraceptive
             agents by females is allowed.

          -  Participation in another study with an experimental drug within 8 weeks before the
             first administration of study medication.

          -  Treatment within the previous 3 months with any drug with a well-defined potential for
             adversely affecting a major organ or system with evidence to this effect.

          -  A major illness during the 3 months before commencement of the screening period.

          -  History of hypersensitivity to the study drug or any related drugs.

          -  History of bronchial asthma.

          -  History of epilepsy.

          -  Relevant history or laboratory or clinical findings indicative of acute or chronic
             disease, likely to influence study outcome.

          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the
             first administration of study medication.

          -  Diagnosis of hypotension made during the screening period.

          -  Diagnosis of hypertension made during the screening period or current diagnosis of
             hypertension.

          -  Resting pulse rate of &gt; 100 beats per minute or &lt; 45 beats per minute during the
             screening period, either supine or standing.

          -  Positive testing for HIV, hepatitis B surface antigen and/or Hepatitis C antibodies.

          -  Positive urine screen for drugs of abuse.

          -  A urine pregnancy test (ß-HCG) either positive or not performed or lactation.

          -  Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step
             Cotinine (COT) Tests).

          -  History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months
             prior to study start.

          -  Significant liver disease, defined as active hepatitis or elevated liver enzymes (e.g.
             aspartate aminotransferase, alanine aminotransferase) &gt;2 times the upper boundary of
             the normal range.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17925</url>
    <description>Approved labelling</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>June 22, 2010</results_first_submitted>
  <results_first_submitted_qc>July 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2010</results_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trazodone Contramid® OAD (Prototype 1) First</title>
          <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in treatment phase I; followed by 2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in treatment phase II; 1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in treatment phase III; and 3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in treatment phase IV. There was a washout period of 7 days between treatment phases.</description>
        </group>
        <group group_id="P2">
          <title>Trazodone Contramid® OAD (Prototype 2) First</title>
          <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in treatment phase I, followed by 1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in treatment phase II; 3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in treatment phase III; and 2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in treatment phase IV. There was a washout period of 7 days between treatment phases.</description>
        </group>
        <group group_id="P3">
          <title>Triticco® First</title>
          <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in treatment phase I; followed by 3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in treatment phase II; 1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in treatment phase III; and 1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in treatment phase IV. There was a washout period of 7 days between treatment phases.</description>
        </group>
        <group group_id="P4">
          <title>Desyrel® First</title>
          <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in treatment phase I; followed by 1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in treatment phase II; 2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in treatment phase III; and 1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in treatment phase IV. There was a washout period of 7 days between treatment phases.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive Trazodone Contramid® OAD (prototype 1) First, Trazodone Contramid® OAD (prototype 2) First, Triticco® First, and Desyrel® First.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC(0-t)</title>
        <description>AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration.
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
        <time_frame>72 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD (Prototype 1)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone Contramid® OAD (Prototype 2)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Triticco®</title>
            <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Desyrel®</title>
            <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC(0-t)</title>
          <description>AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration.
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33883" spread="8069"/>
                    <measurement group_id="O2" value="32445" spread="8868"/>
                    <measurement group_id="O3" value="32928" spread="8313"/>
                    <measurement group_id="O4" value="31841" spread="7398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LS means) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-t) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>102</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.8</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 1)/Triticco®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LS means) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-t) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>105</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.9</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 1)/Desyrel®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LS means) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-t) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>95.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.5</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 2)/Triticco®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LS means) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-t) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>97.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.7</ci_lower_limit>
            <ci_upper_limit>109</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 2)/Desyrel®</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC(0-∞)</title>
        <description>AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
        <time_frame>72 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD (Prototype 1)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone Contramid® OAD (Prototype 2)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Triticco®</title>
            <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Desyrel®</title>
            <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC(0-∞)</title>
          <description>AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35122" spread="8655"/>
                    <measurement group_id="O2" value="33373" spread="9299"/>
                    <measurement group_id="O3" value="34165" spread="9105"/>
                    <measurement group_id="O4" value="32485" spread="7621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-∞) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>102</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.8</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 1)/Triticco®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-∞) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>106</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.1</ci_lower_limit>
            <ci_upper_limit>118</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 1)/Desyrel®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-∞) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>94.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.1</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 2)/Triticco®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-∞) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>98.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.3</ci_lower_limit>
            <ci_upper_limit>110</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 2)/Desyrel®</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Cmax</title>
        <description>Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).</description>
        <time_frame>72 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD (Prototype 1)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone Contramid® OAD (Prototype 2)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Triticco®</title>
            <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Desyrel®</title>
            <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Cmax</title>
          <description>Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1260" spread="402"/>
                    <measurement group_id="O2" value="1475" spread="489"/>
                    <measurement group_id="O3" value="1688" spread="442"/>
                    <measurement group_id="O4" value="2081" spread="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter Cmax is between 75% and 133%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>73.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.2</ci_lower_limit>
            <ci_upper_limit>85</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 1)/Triticco®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter Cmax is between 75% and 133%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>59.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51.5</ci_lower_limit>
            <ci_upper_limit>69.4</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 1)/Desyrel®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter Cmax is between 75% and 133%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.5</ci_lower_limit>
            <ci_upper_limit>96.4</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 2)/Triticco®</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter Cmax is between 75% and 133%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>67.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.4</ci_lower_limit>
            <ci_upper_limit>78.5</ci_upper_limit>
            <estimate_desc>Trazodone Contramid® OAD (prototype 2)/Desyrel®</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t½.z)</title>
        <description>Apparent terminal half-life (t½.z) of trazodone in hours</description>
        <time_frame>72 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD (Prototype 1)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone Contramid® OAD (Prototype 2)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Triticco®</title>
            <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Desyrel®</title>
            <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t½.z)</title>
          <description>Apparent terminal half-life (t½.z) of trazodone in hours</description>
          <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="3.92"/>
                    <measurement group_id="O2" value="10.9" spread="3.55"/>
                    <measurement group_id="O3" value="10.6" spread="3.25"/>
                    <measurement group_id="O4" value="9.77" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the Maximum Concentration (Tmax)</title>
        <time_frame>72 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD (Prototype 1)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone Contramid® OAD (Prototype 2)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Triticco®</title>
            <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Desyrel®</title>
            <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Maximum Concentration (Tmax)</title>
          <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="3.00" upper_limit="24.0"/>
                    <measurement group_id="O2" value="6.00" lower_limit="4.00" upper_limit="24.0"/>
                    <measurement group_id="O3" value="13.0" lower_limit="2.00" upper_limit="16.0"/>
                    <measurement group_id="O4" value="8.50" lower_limit="0.33" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent First Order Terminal Rate Constant [λz]</title>
        <description>Apparent First order terminal rate constant [λz] of trazodone in plasma expressed in 1/hours.</description>
        <time_frame>72 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD (Prototype 1)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone Contramid® OAD (Prototype 2)</title>
            <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Triticco®</title>
            <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Desyrel®</title>
            <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent First Order Terminal Rate Constant [λz]</title>
          <description>Apparent First order terminal rate constant [λz] of trazodone in plasma expressed in 1/hours.</description>
          <population>The dataset for pharmacokinetic analysis comprised the 19 subjects who completed the study as per protocol.</population>
          <units>1/hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.02"/>
                    <measurement group_id="O2" value="0.07" spread="0.02"/>
                    <measurement group_id="O3" value="0.07" spread="0.02"/>
                    <measurement group_id="O4" value="0.08" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Trazodone Contramid® OAD (Prototype 1)</title>
          <description>1 * 300 mg Trazodone Contramid® OAD (prototype 1) tablet test product dosed in either treatment phase.</description>
        </group>
        <group group_id="E2">
          <title>Trazodone Contramid® OAD (Prototype 2)</title>
          <description>1 * 300 mg Trazodone Contramid® OAD (prototype 2) tablet test product dosed in either treatment phase.</description>
        </group>
        <group group_id="E3">
          <title>Triticco®</title>
          <description>2 * 150 mg Triticco® tablets (at 07:30 and 19:30) reference product dosed in either treatment phase.</description>
        </group>
        <group group_id="E4">
          <title>Desyrel®</title>
          <description>3 * 100 mg Desyrel® tablets (at 07:30, 15:30 and 23:30) reference product dosed in either treatment phase.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypotensive shock</sub_title>
                <description>As reported</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypotension with convulsions</sub_title>
                <description>as reported</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The scientific results from this study are the property of the Sponsors, ie, Labopharm Inc., Canada and A.C.R.A.F. S.p.A., Italy. No data reported in the final integrated clinical trial report of this study will be used for publication in scientific journals and/or for presentation at scientific meetings without a previous agreed written consent between the Sponsors.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

